3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Squamous Cell Carcinoma of Head and Neck
4
Pancreatic Neoplasms
3
Triple Negative Breast Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Hepatocellular
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Melanoma
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Neuroendocrine
1
Anophthalmia with pulmonary hypoplasia
1
Interventions
pembrolizumab
12
Pemetrexed
9
Cisplatin
9
Nivolumab
8
Carboplatin
8
Ipilimumab
7
Cyclophosphamide
6
fludarabine
5
durvalumab
4
tremelimumab
2
Radiotherapy, Intensity-Modulated
2
Gemcitabine
2
Cerebral Decortication
2
tocilizumab
1
tislelizumab
1
tazemetostat
1
sotorasib
1
ruxolitinib
1
osimertinib
1
olaparib
1
obinutuzumab
1
naptumomab estafenatox
1
fludarabine phosphate
1
decitabine and cedazuridine drug combination
1
bintrafusp alfa protein, human
1
avelumab
1
atezolizumab
1
Tumor Burden
1
Temozolomide
1
Tablets
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Mesothelioma
×
budigalimab
×
1 year
×
Clear all
No trials found.